NCT06745323

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 252 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

Conditions

• Small Cell Lung Cancer (SCLC)

Interventions

Type	Name	Description
DRUG	Tarlatamab	Tarlatamab will be administered by IV infusion.

Timeline

• Start date: 2025-02-26
• Primary completion: 2029-02-09
• Completion: 2029-02-09
• First posted: 2024-12-20
• Last updated: 2026-03-03

Locations

78 sites across 16 countries: United States, Argentina, Australia, Belgium, Brazil, China, France, Germany, Greece, Italy, Japan, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study